Logo image of CERO

CERO THERAPEUTICS HOLDINGS I (CERO) Stock Overview

USA - NASDAQ:CERO - US71902K4022 - Common Stock

1.79 USD
-0.09 (-4.79%)
Last: 10/29/2025, 7:24:57 PM
1.33 USD
-0.46 (-25.7%)
After Hours: 10/29/2025, 7:24:57 PM

CERO Key Statistics, Chart & Performance

Key Statistics
Market Cap3.35M
Revenue(TTM)N/A
Net Income(TTM)-41912900
Shares1.87M
Float1.83M
52 Week High895.4
52 Week Low1.72
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-223.77
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2021-10-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CERO short term performance overview.The bars show the price performance of CERO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

CERO long term performance overview.The bars show the price performance of CERO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CERO is 1.79 USD. In the past month the price decreased by -67.16%. In the past year, price decreased by -98.92%.

CERO THERAPEUTICS HOLDINGS I / CERO Daily stock chart

CERO Latest News, Press Relases and Analysis

CERO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.26 397.72B
AMGN AMGEN INC 13.38 157.08B
GILD GILEAD SCIENCES INC 15.31 147.04B
VRTX VERTEX PHARMACEUTICALS INC 24.63 106.97B
REGN REGENERON PHARMACEUTICALS 14.51 69.20B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.13B
ARGX ARGENX SE - ADR 89.25 50.61B
INSM INSMED INC N/A 35.29B
ONC BEONE MEDICINES LTD-ADR 5.07 34.58B
NTRA NATERA INC N/A 26.46B
BNTX BIONTECH SE-ADR N/A 24.85B
BIIB BIOGEN INC 9.24 21.68B

About CERO

Company Profile

CERO logo image CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Company Info

CERO THERAPEUTICS HOLDINGS I

201 Haskins Way, Suite 230

South San Francisco CALIFORNIA US

Employees: 8

CERO Company Website

CERO Investor Relations

Phone: 6504072376

CERO THERAPEUTICS HOLDINGS I / CERO FAQ

What does CERO do?

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.


What is the stock price of CERO THERAPEUTICS HOLDINGS I today?

The current stock price of CERO is 1.79 USD. The price decreased by -4.79% in the last trading session.


Does CERO stock pay dividends?

CERO does not pay a dividend.


How is the ChartMill rating for CERO THERAPEUTICS HOLDINGS I?

CERO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


What is the GICS sector and industry of CERO stock?

CERO THERAPEUTICS HOLDINGS I (CERO) operates in the Health Care sector and the Biotechnology industry.


How is the valuation of CERO THERAPEUTICS HOLDINGS I (CERO) based on its PE ratio?

CERO THERAPEUTICS HOLDINGS I (CERO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-223.77).


CERO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CERO Financial Highlights

Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -223.77. The EPS increased by 63.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -675.76%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%71.35%
Sales Q2Q%N/A
EPS 1Y (TTM)63.38%
Revenue 1Y (TTM)N/A

CERO Forecast & Estimates

8 analysts have analysed CERO and the average price target is 45.9 USD. This implies a price increase of 2464.25% is expected in the next year compared to the current price of 1.79.


Analysts
Analysts82.5
Price Target45.9 (2464.25%)
EPS Next Y90.59%
Revenue Next YearN/A

CERO Ownership

Ownership
Inst Owners20.48%
Ins Owners2.67%
Short Float %10.54%
Short Ratio0.63